In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Statistics Q1 2010

Executive Summary

In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.

You may also be interested in...



Biotech Backers Learn To Live With Exit-By-Earn-Out

Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?

Teva Wins ratiopharm, As it Moves to Solidify its EU Position

The purchase of the privately held ratiopharm Group solidifies Teva's number one position in the European generics industry and fits well with its goal of expanding the gap between itself and competitors. Importantly, it gives Teva a firm standing in Germany, where it had been a minor player.

GSK Bolsters Orphan Drug Discovery By Signing Antisense Deal With Isis

Under the deal, which has all the hallmarks of a GSK option-based alliance, Isis gets $35 million upfront, and will deliver five drugs through PoC.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel